D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical ...

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Want to improve your health and fitness in 2025? The good news is you don’t need a drastic lifestyle overhaul to make a difference. Small but impactful changes can significantly improve your wellbeing ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

snu.ac.kr Background/Aims To provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in ...

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients ...

Cashews are not only delicious but also packed with essential nutrients that support overall health. Here are 7 cashew ...